Claret Capital Partners has raised a total of €575 million, consisting of €440 million in Fund IV commitments and €135 million in a discretionary mandate. The fund attracted investments from pension plans, insurance companies, family offices, public and institutional investors, and private wealth investors via an ELTIF structure. The firm also utilizes discretionary co-investment partnerships.
Since 2013, the firm has invested over €1.5 billion across more than 210 companies in the technology, life sciences, and impact sectors. The team provides debt solutions to minimize dilution for entrepreneurs. Typical loan amounts range from €2 million to €100 million, supporting organic growth, acquisitions, and R&D.
Approximately 32% of Fund IV has already been deployed to 27 companies, including Billie, Cinclus Pharma, PRODA, and Surfe. In September 2025, the firm had reached a second close of over €350 million for this fund. Additionally, a €72 million Opportunity Fund was launched in May 2023 for follow-on funding.
The firm's Fund III, which closed in 2022 with €297 million, has resulted in strategic exits including Cytora, Endomag, and Logpoint, as well as an IPO on NASDAQ for Abivax. Claret is now expanding its presence in European innovation hubs, adding team members in Paris and planning for a Berlin office.
